The Library / Market Analysis
Market Analysis
8 issuesNumbers, reimbursement, short reports, and market reads.
Is Transverse Tibial Transport the Next Gold Rush?
Six companies already have systems. The evidence is promising but unfinished, the wound indication isn't on the label, and scope of practice may decide who gets to use it. Plus HyperFlex walks into the lion's den, and every AOFAS 2026 industry lab in one place.
Treace and Paragon 28 by the Numbers, Plus Lapidus Launches
FY2023 results for the two public pure-plays, and a newcomer in biologics.
The Treace Report: Inside Culper Research's Short Thesis
An activist short seller accuses Treace of fraudulent coding. We read all 21 pages.
The Syndesmosis Market, Reviewed
The soft tissue battle heats up as Paragon 28 and Medline UNITE debut new products.
The CMS Amniotic Clawback Is Coming
Medicare wants its money back, plus a new surgeon CMO and a run of fresh launches.
Surgical Volumes Rebound, and a New Total Ankle Enters the Field
Case volumes recover faster than forecast, plus a CE mark and a new total ankle.
Hammertime: The Decade of the Hammertoe Implant
Plus AdvaMed's rep reentry rules, April's 510(k) clearances, and a Vantage TAR walkthrough.
Arthrex Goes Direct-to-Patient with AnkleSprain.com
Two million ankle sprains a year, and a company building the landing page for them.
← Back to the library